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TECHNICAL NOTE
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Glomerular filtration rate (GFR) is the standard measure of
renal function and serial measurements often are used to
describe the course of renal disease in clinical studies including
controlled clinical trials. Serum creatinine (Sr), commonly
used to estimate renal function, is now recognized as insuffi-
ciently accurate for this purpose [1, 2]. The reference standard
for estimating GFR is the renal clearance of inulin (C1). The
plasma C1, derived from steady state level and input rate, is
equally suitable [3]. Although inulin is the ideal marker, isotopic
and unlabeled iothalamate are both used to estimate GFR from
the renal ['1—6] or plasma [5, 7, 8] clearance of iothalamate (Cr0).
Even these clearance methods, however, are sufficiently time
consuming and expensive to constitute an impediment to accu-
rately estimating GFR in clinical studies, particularly in chil-
dren.
Plasma clearance is measured either by giving a single bolus
injection of a marker and measuring its fractional disappearance
rate from plasma [9] (single-injection plasma clearance) or by
infusing a marker to a steady state and measuring its input rate
divided by its plasma concentration [101 (steady-state plasma
clearance). Either of the two plasma clearance methods is
preferred in children or patients with voiding dysfunction
because collecting timed urine samples as required for renal
clearances often is impractical.
We describe a method for measuring the steady-state plasma
C10. lothalamate is delivered subcutaneously from a very
accurate portable pump at a constant rate for a calculated
minimum infusion time. Clearance is calculated from input rate
and the steady state plasma level.
Methods
Principle
The method uses a constant infusion of iothalamate to
achieve a steady-state plasma concentration (S10). Unlabeled
undiluted iothalamate is delivered subcutaneously, rather than
intravenously, at a constant rate from the small MiniMed
portable pump (MiniMed Technologies, Sylmar, California,
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USA) which commonly is used to deliver insulin to patients
with diabetes. The delivery rate is accurate (±2%), the infusion
comfortable, and the uptake steady. A programmable pocket
calculator or personal computer calculates the loading dose,
infusion rate and minimum infusion time. After the infusion is
started, patients go about their usual activities until a blood
sample is drawn once the minimum infusion time has elapsed
(usually 6 to 24 hours); the infusion is then discontinued and the
pump recovered. Plasma C10 is calculated from the rate of
iothalamate input divided by S10 when S10 is at a steady state.
Criteria for establishing steady state conditions are defined in
the Appendix.
Infusion
lothalamate meglumine (Malinkrodt Medical Inc., St. Louis,
Missouri, USA; brand name, Conray 60) (—450 mg/mi of
iothalamic acid) is drawn into a 3 ml syringe that accompanies
the pump. The pump is programmed to deliver iothalamate at a
constant rate (between 0.002 and 0.7 ml per hour with an
accuracy of through tubing and a 26 gauge silastic
catheter provided with the pump (Fig. 1). The catheter usually
is placed into abdominal subcutaneous tissue over a guide and
affixed to the skin with a butterfly. The infusion runs for the
calculated minimum infusion time or longer.
Procedure
All protocols were approved by the Committee on Human
Research, UCSF. Each subject, patient or guardian read and
signed the appropriate consent form.
The patient's age, weight, height, and 5Cr were used to
calculate the loading dose, the patient's estimated GFR from a
modification of the Ht/Sr equation [11] (which we term the
Ht/SrGFR), the infusion rate and the minimum infusion time.
For adults an alternate method was used to estimate GFR
(Appendix). For children up to twelve years of age we also
estimated normal GFR for age and weight [12].
A suitable dilution is made for the loading dose. The pump is
programmed to set the infusion rate. The syringe and tubing are
loaded with undiluted iothalamate, care being taken to be sure
that connections are tight and the line is cleared of air bubbles.
A sample of the undiluted infusate and a serum blank (Se) are
obtained. The loading dose is given, the pump is activated at a
relatively high infusion rate to maintain the needle and catheter
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Fig. 1. The MiniMed pump, the line, and the 26-gauge silastic catheter with stylet used to insert catheter. The stylet is removed and the butterfly
fixes the hub of the catheter to the skin. The audiocassette is displayed to illustrate the size of the pump.
weight as we have described previously [11]. Detailed calcula-
tions for these purposes are included in the Appendix.
Results
We did three studies to validate this method:
1. Purpose and protocol
The first study had four objectives: to determine whether
uptake was steady; to compare the time required to achieve
steady state without giving a loading dose with that when a
loading dose was given; to evaluate reproducibility of the
method repeated in the same subject; and to determine whether
the subcutaneous infusion of undiluted iothalamate was well
tolerated.
Each of four normal male volunteers (aged 21 to 32) under-
went a subcutaneous infusion begun without any loading dose;
blood samples were obtained periodically for up to 18 hours
after starting the infusion. Each volunteer was restudied within
two weeks, at which time the protocol was the same except that
a loading dose (2 mg/kg) was given.
Results. The uptake curve of lothalamate in the four in-
(1) stances where no loading dose was given was similar to the
curve that would be obtained from a constant intravenous
infusion begun at zero concentration (Fig. 2). The time required
to achieve a steady state was shortened when a loading dose
clear of any air bubbles, the catheter is inserted into the
abdominal subcutaneous tissue and fixed with a butterfly, and
the pump is reset to the calculated infusion rate. A second
serum sample (S1) is taken one hour post-loading dose to
compare with the steady-state serum sample (S10); S10 is
obtained at a convenient time after the minimum infusion time
has passed. The serum samples and a dilution of the infusate
sample are analyzed for iothalamate.
Analysis
lothalamate is determined by high pressure liquid chromatog-
raphy using a reverse phase column (C18 5 Ultrasphere) with
a mobile phase of water:acetonitrile:phosphoric acid (990:10:
0.5) at pH 2.65 and a flow rate of 1.5 mi/mm. UV absorbance is
monitored at 236 nm; the retention time is 13 minutes [131.
Calculations
The absolute C10 (mi/mm) is calculated from the following
equation:
Infusion10 (mg/mi) . Infusion rate (ml/hr)
C10 (mi/mm) =
S10 (mg/mi) 60 mm/hr
The result may be adjusted to standard surface area (mi/mint
1.73 m2) and, for children, to percent normal (% nl) for age and
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Fig. 2. The S,, curves of one of the subjects in the first study showing
the plasma uptake curve when no loading dose was given (0) and when
a loading dose was given (•). The uptake to steady state when no
loading dose was given was the same as one would see if iothalamate
was given intravenously except for a small initial delay. The loading
dose shortened the time to near steady state.
was given. There was good agreement when a study was
repeated in the same subject (Fig. 2, Table 1). The steady state
was maintained when the infusion was extended (Fig. 3). None
of the subjects experienced any pain, discomfort or skin reac-
tion at the site of the infusion or any evidence of an allergic
reaction; this also has been the case for all other subjects and all
patients we have studied.
2. Purpose and protocol
The second study compared the plasma C10 with the renal C10
and the renal C1,, measured simultaneously. Five normal male
subjects aged 21 to 34 were admitted to the Clinical Research
Center, SFGH and a subcutaneous infusion of iothalamate was
begun in the evening; they were fasted overnight. At 8 a.m.
each subject was given a loading dose of inulin (50 mg/kg) and
10 mI/kg water to drink. In each a constant infusion of inulin
was started to sustain a serum level of 0.15 mg to 0.20 mg/mi.
Throughout the study each subject drank a volume of water
equal to the volume of urine passed plus insensible water loss.
Following a 90-minute equilibration period four to six sponta-
neously voided timed urine samples were collected; these were
bracketed by blood samples. The renal clearances of iothala-
mate and inulin were calculated for each period and the average
was used for that clearance. Plasma C10 was calculated as
described.
Results. The ratios of the plasma C10 to that of its renal
clearance and to the renal C1,, are illustrated in Table 2. Neither
differed significantly from 1.0.
3. Purpose and protocol
The third study evaluated the practicality of this method for
measuring the steady-state plasma C10 in children with varying
degrees of renal impairment. A C10 was measured in association
with other clinical studies in twenty-five patients who ranged in
age from six months to nineteen years of age, had evidence of
renal disease, and were being followed by the pediatric nephrol-
Subject no.
C10 without i.v.
priming dose
mI/mm
Time to
S10 (N)
hr
C10 with i.v.
priming dose
mI/mm
Time to
S10 (N)
hr
1 122 8 (2) 120 6 (4)
2 117 8(3) 98 1(10)
3 122 8 (6) 123 2 (8)
4 138 6 (7) 140 1(9)
Mean 5D 124.8 9.1 7.5 1 120.3 17.3 2.5 2.3
Mean difference 4.5 4.9
SD
ogy or urology service. Twenty-three were admitted to the
Pediatric Clinical Research Center, UCSF and the infusion was
started; the pump was secured in a cloth pouch. Two had the
infusion started as outpatients; the patients then were sent
home with instructions to maintain usual activities and return
the next day when the final blood sample was obtained and the
pump recovered. We also did the following: (a) calculated the
ratio of the C10 to Ht/SrGFR in all twenty-five patients to
determine whether that ratio was greater than 0.6 in accordance
with the assumptions underlying the calculation of the minimum
infusion time as described in the Appendix. (b) We measured
the ratio of S1 to S10 in fourteen patients; (c) measured the
plasma C1,, simultaneously in five patients; and (d) obtained in
eight patients, in whom an extended study was practical, five or
more blood samples that were drawn over a period of 12 to 50
hours following the bolus dose; all these samples were obtained
after the minimum infusion time had passed. The coefficient of
variation (c.v.) of these multiple samples for each patient was
considered an index of variability during the steady state.
Results. The studies were done without complication. In one
case a connection was not tight and the study had to be
repeated. The C10 is expressed as the absolute GFR, GFR
adjusted to standard body surface area, and as % nl GFR for age
and weight [Ii] (Table 3). We also found that: (a) the C10/(Ht!
SGFR) was >0.6 in every case (Table 3); (b) the ratio of S1
to S10 was between 0.6 and 2.4 in all but one of 14 instances
where it was determined; (c) the ratio of the C10/C1,, for the five
patients who had both done was 1.01 0.14 (mean SD); and
(d) the c.v. for the serial serum S10 values of eight children who
had five or more samples obtained at steady state averaged
6.2% (Table 4).
Discussion
Previous work and our findings support the use of the
steady-state plasma C1,, as an accurate estimate of GFR as long
as steady state conditions can be verified. Cole and her col-
leagues [10] have shown that the steady-state plasma C1,, in
children is equal to its renal clearance, and Mak et al [51 have
shown the steady-state plasma C10 in children is the same as the
renal C10 and C10. One of us (MAH) and others [14] have
0.03
J
::
0.00
Table I. GFR measurement with and without an i.v. priming dose of
lothalamate in four healthy men
0 5
Plasma clearance of lo was measured using an extended subcutane-
ous infusion (s.c.) infusion of 10, first without; and then one week later,
10 15 20 with an iv. priming dose of lo.
Time to S10: Hours needed to reach steady state plasma Jo levels,
with a coefficient of variation of < 10% between blood samples. (N) =
Number of blood samples at S10.
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Table 2. Comparison of the plasma clearance of lothalamate with the
renal clearances of lothalamate and inulin in five healthy men
Subject no. PC1,, RC1,, RC1 PCIO/RCIQ PCI,,IRCb,
1 180 165 173 1.09 1.04
2 125 135 123 0.93 1.02
3 153 148 153 1.03 1.00
4 143 153 169 0.93 0.90
5 132 120 126 1.10 1.05
Mean so 1.02 0.08 1.00 0.06
0 10 20 30 40 50 60
Time, hours
Fig. 3. The stability of Sj, is illustrated in a patient infused for 52 hours(study 3). The t½ calculated to be 7 hours. The Approx GFR (Ht/Sr)
predicted the C1,, closely following a bolus dose, steady state reached
promptly.
reported steady-state plasma C1,, was the same as the steady-
state plasma C1 when both were infused intravenously. In this
study we confirm that the steady-state plasma C10 and the renal
C1,, and C1 were the same when the iothalamate was given
subcutaneously as described, and the inulin was given intrave-
nously to five volunteers with normal renal function and five
patients with reduced renal function.
This method has several features that make it suitable for use
in children in whom the serial estimate of GFR is indicated. It
is practical: undiluted iothalamate is delivered subcutaneously
at a slow constant rate by a portable, accurate infusion pump;
the patient is free to follow usual activities after the hour
required to initiate the study and returns only to have the steady
state sample (S1,,) drawn and the pump recovered. It is safe: the
iothalamate is not radioactive; the risk of an allergic reaction is
very low and the patients are under observation for one hour
after being given the loading dose to check for this possibility.
The method accurately measures the plasma C10. We used
two strategies to affirm that we had reached a steady state
which we defined as a value that was within 100 10% of true
steady state and did so within the calculated minimum infusion
time (usually between 6 to 24 hours following the loading dose).
First, we gave a loading dose (initially 2 mg/kg) calculated so
that the priming level, S1, would likely be between 0.6 and 2.4
of the steady state level (S10), and verified that it was in thirteen
of fourteen cases. In the one exception serial S1,, values
obtained after the calculated minimum infusion time had
elapsed established that a steady state had been reached, Using
a loading dose that meets the criteria shortens the minimum
infusion time by approximately a third. [We now double the
loading dose (4 mg/kg; Appendix) to be more confident that S1
will be between 0.6 and 2.4 of S1,, and routinely check to see
that it is]. Second, we estimated a tV2 for a clearance that would
be 60% of Ht/SrGFR and used this to derive a minimum
infusion time (2.5 . est t½). The t½ we estimated would exceed
the true t'/2 so long as C10 (Ht/SrGFR) exceeded 0.6; it did in
all cases (Table 4). When these conditions are met the true
minimum infusion time to steady state is less than the calculated
one.
To further demonstrate whether a steady state has been
reached an additional sample may be drawn; it is well to wait at
least another one fourth of the estimated t½ [15]. This often is
impractical when studies are done in children or in an outpatient
setting. In the eight children in whom we obtained additional
samples for that purpose, we verified that we achieved and
sustained a steady state. The other checks we describe make
the test redundant. When results are not within the limits we
have set, the study should be repeated.
Several clinics, recognizing that the estimation of GFR from
Scr is inadequate for clinical follow up, have adopted clearance
methods that use an isotope as a marker and either measure
renal clearance or single-injection plasma clearance. A few
pediatric clinics use the steady-state plasma Cth for this pur-
pose. Each of these methods requires the patient to be in clinic
for from 5 to 8 hours and requires a comparable amount of staff
time. For patients or parents of children this often means a
missed day of work. Single-injection plasma clearances are less
accurate [16j. The direct cost for each clearance that was
reported to us in an informal survey varied between $150 to
$400. We calculated costs for the method we describe to be less
than $100 under comparable conditions (>30 tests per year for
5 years); this estimate includes amortizing the HPLC equipment
and the pumps. In cases where it is inconvenient for a patient to
return to the central clinic for the S10 sample, it would be
practical to have the sample drawn in a laboratory near to the
patient and have the sample and pump returned by a commer-
cial delivery service.
This method makes it practical and economical to make
accurate estimates of GFR serially in children either in a single
center doing >30 tests per year or multiple centers participating
in a controlled clinical trial in which the total averages >50 per
year over a five year period. The procedure can be done on an
outpatient or inpatient basis without requiring that staff be
specially trained and dedicated to that method. The cost per test
projects to be less than the reported costs of present methods.
The accuracy in our hands is equal to that reported for the other
methods being used. These considerations lead us to conclude
that this method makes accurate serial estimates of GFR
practical in patients, particularly in children and others in whom
the collection of timed urine samples is problematic.
Reprint requests to Amira Al-Uzri, M.D., do Pediatric Nephrology
Division, University of California, San Francisco, 533 Parnassus
Avenue, Room U585, San Francisco, CA 94143-0748, USA.
0.010
:i
0.008
0.006
0.004
0)0
8 0.0020
0.000 '
Abbreviations are: PC10, plasma clearance of lothalamate; RC10,
renal clearance of lothalamate; RC10, renal clearance of inulin.
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Table 3. Clearance data on twenty-flye patients
Pt.
no.
Age
years
Ht
cm
Wt
kg
SA
m2
ni GFR
mi/mm
Sr
mg/dl
Ht/ScrGFR C10 C10/SA
ml/min/1.73 m2
%nl
GFR Cio/(Ht/SrGFR)mi/mm
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
0.67
0.92
1.08
1.58
2.58
3.67
5.17
7.08
9.42
10.25
0.58
12.00
19.00
4.17
6.08
2.00
0.42
6.08
0.92
2.42
14.00
9.92
12.00
14.58
4.83
66.0
70.5
73.6
78.6
88.9
81.5
109.2
113.0
132.1
123.8
68.0
155.6
130.0
88.9
115.0
78.5
50.0
111.7
73.0
92.0
100.0
131.0
152.0
102.5
84.0
5.9
9.1
11.4
10.5
14.7
12.3
18.0
19.1
26.7
24.3
8.9
49.5
30.0
12.0
20.7
10.0
3.4
22.2
10.1
17.0
68.0
47.0
38.4
70.5
10.7
0.33
0.43
0.49
0.48
0.61
0.54
0.74
0.77
0.98
0.91
0.42
1.46
1.04
0.55
0.81
0.47
0.22
0.83
0.46
0.67
1.46
1.33
1.26
1.50
0.50
19.0
27.1
32.3
33.3
44.9
44.1
58.0
63.8
79.0
77.1
24.5
107.5
95.5
44.8
64.2
34.1
11.2
66.4
29.0
47.8
125.2
101.6
96.9
127.8
43.6
0.5
0.4
0.6
0.3
0.8
1.1
0.7
0.7
0.9
3.3
0.6
0.9
1.2
3.2
0.5
1.0
0.2
0.8
0.8
0.5
0.8
1.0
0.8
0.6
0.6
11.4
19.7
15.8
33.0
17.6
10.3
29.9
32.4
37.6
8.9
12.3
65.8
29.3
4.0
48.6
9.6
14.4
30.3
10.9
32.0
47.4
45.3
62.5
66.6
18.3
8.7
16.0
22.3
25.0
40.2
9.4
40.0
41.3
44.0
7.8
11.0
89.0
26.3
2.9
41.3
8.5
10.6
33.7
8.8
33.3
87.0
53.8
88.4
76.0
17.9
45.4
64.4
78.2
89.2
114.0
30.4
93.8
92.5
77.4
14.8
45.4
105.2
43.7
9.2
88.0
31.2
83.0
69.9
33.0
86.2
103.3
70.0
120.9
87.7
61.6
45.8
59.0
69.1
75.0
89.5
21.3
69.0
64.7
55.7
10.1
44.9
82.8
27.5
6.5
64.3
24.9
94.4
50.8
30.4
69.7
69.5
52.9
91.2
59.5
41.0
0.76
0.81
1.42
0.76
2.28
0.91
1.34
1.27
1.17
0.88
0.89
1.35
0.90
0.73
0.85
0.88
0.74
1.11
0.80
1.04
1.84
1.19
1.41
1.14
0.98
Avg
SD
6.06
5.14
98.78
27.31
22.82
17.99
0.77
0.37
60.0
32.8
0.91
0.73
28.6
18.3
33.7
26.3
69.5
30.1
54.8
24.0
1.10
0.36
Table 4. Summary statistics of S0 on 8 patients who had more than
five values over 12 to 50 hours
N Avg of S10mg/mi
SD of
Avg
CV
%
5 0.55 0.03 4.6
5 1.41 0.07 5.0
7 1.03 0.14 13.3
5 1.12 0.05 4.5
7 0.95 0.03 2.7
5 0.96 0.06 6.3
5 1.40 0.05 3.3
5 1.44 0.13 9.3
N, number of blood samples at S; data are mean SD 6.13 3.54.
Appendix
The loading dose (4 mg/kg when ECF volume is estimated to be 200
mI/kg) is calculated to achieve a concentration of iothalamate at one
hour that exceeds the anticipated steady state S10 if C10 equals Ht/Scr
GFR.
Loading dose (mg) = 0.02 (mg/mI) ECF vol (mI/kg) body wt (kg)
(2)
The infusion rate is calculated to sustain a steady state S1, of 0.02
mg/ml if the measured GFR (C10) equals the Ht/ScrGFR. So long as C10
varies between 0.6 and 2.4 of the Ht/ScrGFR the infusion time as
calculated is sufficient for serum iothalamate to achieve a steady state
concentration as we define it.
Est GFR (mI/mm) = 0.45 . [Ht (cm)/Scr (mg/dl)] . (SA/l .73 m2)
(3)
We use the constant 0.45 for all ages rather than to introduce
age-dependent higher values as recommended by the original authors
because this increases the likelihood that the C1, will be >60% of the
Ht/SrGFR. Taking 60% of the Ht/ScrGFR to calculate the estimated
t½ assures that the true tV2 will be less so long as the C10 is >60% of the
Ht/ScrGFR; the infusion time under these conditions will exceed 2.5
true t½s (see equation 4). Surface area (SA) used in the equation may
be derived from a nomogram or from the height/weight equation
described by Haycock and his associates [17]:
SA = 0.024265 . weight°5378 height°396
It is convenient to include the latter as part of the computer program.
Other formulas are used for estimating GFR in adults [18].
The infusion rate (ml/hr) is calculated from the term:
Ht/Sc-GFR (mi/mm) . 0.02 mg/mI 60 mm/hr . (1/450 mg/mI)
Using a priming dose so that the ratio of S to S10 will be between 0.6
and 2.4 reduces the minimum infusion time by shortening the number of
true t'/2S required to reach the steady state.
The minimum infusion time is based on an assumption that C10 is at
least 60% of the est GFR and that the ratio of S1 to S10 is between 0.6
and 2.4.
Minimum infusion time = 2.5 . In 2/[0.6 . (Ht/SrGFR)/ECF]
(4)
If the patient is edematous a larger ECF volume must be used in the
equations.
If total infusion volume (infusion rate . infusion time) exceeds 3 ml
arrangements must be made to refill the syringe. This is unlikely to be
required except in patients who have very low clearances and are in the
adult weight range mandating a long infusion time or where, for
convenience, an extended infusion time is planned. Patients can be
trained to refill the syringe.
Normal GFR for age and weight for children up to twelve years of age
is calculated from the child's age and weight according to the following
equations:
where
nI GFR (age & wt) = z3 + 0.1293 . z,
1706 Al-Uzri et al. Accurately measuring GFR in patients
= 0.7434 + [0.6956 log (5 + age)] + (1.47 log wt).
Age is in months and weight is in kg.
Percent normal for age and weight (% ni) is computed from the
equation:
%nl GFR = (C.Io/nl GFR) 100%
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